Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
In trials, medication treatments may be more standardized and less influenced by sociocultural variables than lifestyle and surgical interventions
While transdermal patch delivery systems are under investigation, all commercially available GLP-1 therapies require subcutaneous injection (semaglutide, liraglutide, dulaglutide, tirzepatide) or oral administration (Rybelsus)
Excretion of metformin into breast milk and the effect on nursing infants
PMID: 39219539
Beauty Bank Membership: Elevate Your Aesthetic Journey at Admire At Admire Aesthetics, our exclusive Beauty Bank Membership is designed to enhance your wellness and radiance